An international team identified 80 genomic regions linked to endometriosis risk by integrating multi-omic data with a massive cohort.
Endometriosis affects approximately 10% of women worldwide, yet the biological roots of this chronic systemic condition remain largely obscured by decades of underfunded research.
On November 20, 2026, researchers published a landmark genome-wide association study in Nature Genetics that alters how geneticists understand the disease.
The international team analyzed data from roughly 1.4 million women across multiple ancestries, establishing a new statistical baseline that includes 105,869 diagnosed cases.
By integrating multi-omic data with this massive cohort, the authors identified 80 distinct genomic regions linked to endometriosis risk. Thirty-seven of these loci are entirely new discoveries, and five overlap directly with adenomyosis.
Researchers link genetic variants to disease pathways and treatments
The analysis goes beyond simply mapping gene locations. Researchers pinned down putative causal variants behind more than 50 of these genetic associations. Transcriptomic, epigenetic, and proteomic evaluations across various tissues tied the disease risk directly to biological pathways governing cell differentiation, immune function, hormonal regulation, tissue remodeling, and systemic inflammation.
These molecular insights opened immediate avenues for pharmaceutical investigation. Drug-repurposing analyses highlighted existing compounds already deployed for breast cancer treatment, hormonal contraception, and preterm birth prevention as potential therapeutic candidates for endometriosis patients.
Genetic risk scores connect endometriosis to chronic pain and anxiety
Polygenic risk scores calculated in the study revealed direct genetic intersections with specific clinical symptoms. Endometriosis polygenic risk interacted heavily with patient experiences of chronic abdominal pain, severe anxiety, migraines, and persistent nausea.
These findings provide biological backing for clinical observations that have long linked the condition to broader neurological and gastrointestinal manifestations. The research team also noted conflicts of interest in their publication disclosures.
R.P. reported editorial compensation from the journal Complex Psychiatry and a research grant from Alkermes outside the scope of the study. I.F. disclosed a role as cofounder and co-owner of Sur180 Therapeutics, a firm developing a new endometriosis treatment, alongside serving as Chief Scientific Officer for Nura Health, which works on non-invasive diagnostic solutions.
Answers common questions about study size and findings
How many women were included in the genome-wide association study?
The study evaluated approximately 1.4 million women, which incorporated 105,869 confirmed endometriosis cases across multiple ancestral backgrounds.
How many new genetic loci did the researchers discover?
The analysis identified 80 genomic regions associated with the condition, yielding 37 previously unknown loci, five of which also show connections to adenomyosis.
Nature Genetics, the journal that published the study, was established in 1992 as the first of the Nature Research journals and has maintained a focus on the genetic basis of common and complex diseases. According to Journal Citation Reports, it holds a 2025 impact factor of 25.5, ranking second among 191 journals in the “Genetics & Heredity” category.
What existing treatments did the multi-omic analysis highlight?
The computational drug-repurposing screening pointed toward medications currently utilized in breast cancer therapy, hormonal contraception, and the prevention of preterm birth.